Endo Pharmaceuticals clinical trials

Acquired by Keenova Therapeutics plc, Jul 31, 2025 · source ↗

The registry lists 99 studies whose lead sponsor is Endo Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 21, 2025.

Studies

Recruiting first, then most recently updated. Showing 50 of 99. List all 99 → · All Keenova Therapeutics plc studies →

• Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar FibromatosisCompletedNCT05254457Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With HypogonadismCompletedNCT04456296Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the ButtocksCompletedNCT05419505Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's ContractureTerminatedNCT05877066

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's DiseaseTerminatedNCT05873595

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Topical Lidocaine Patch in Low Back PainCompletedNCT00904540Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back PainCompletedNCT00904020Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual MigraineCompletedNCT00475514Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Vantas Implant Retrieval StudyCompletedNCT01013025

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Study of Histrelin Subdermal Implant in Patients With Prostate CancerCompletedNCT01394263Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)CompletedNCT04381117

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain ConditionsCompletedNCT00904202Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute PainCompletedNCT00226395Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant PainCompletedNCT00226421Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate CancerCompletedNCT01697384Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant PainCompletedNCT00225797Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) HeadachesCompletedNCT01035983Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual MigraineCompletedNCT00644033Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety and Efficacy of EN3835 in Participants With Frozen ShoulderCompletedNCT04496167Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)CompletedNCT03526549Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)CompletedNCT03632993Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock CelluliteCompletedNCT04677712Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With LaxityCompletedNCT05249257

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)TerminatedNCT04680156

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection TechniquesCompletedNCT04580303Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Histopathology Following CCH InjectionCompletedNCT04236635Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Real World CCH Study in Adult Females With CelluliteCompletedNCT04170296Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsTerminatedNCT02687451Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult WomenTerminatedNCT04209530Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsCompletedNCT01210352Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety and Pharmacokinetics of Vasopressin in Healthy VolunteersCompletedNCT04093050Phase 1

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Histrelin Subcutaneous Implant in Children With Central Precocious PubertyCompletedNCT00779103Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety and Effectiveness of EN3835 in the Treatment of EFP in WomenCompletedNCT03329989Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced ChildrenSuspendedNCT04681027Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric SubjectsTerminatedNCT00765856Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)CompletedNCT02942160Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Effectiveness and Safety of EN3835 in the Treatment of Cellulite in WomenCompletedNCT03446781Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in WomenCompletedNCT03428750Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFPCompletedNCT03675685Phase 1

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in WomenCompletedNCT03893890

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.CompletedNCT00801398Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies DiseaseCompletedNCT02298829

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's DiseaseCompletedNCT00533273Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's DiseaseCompletedNCT00528840Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's DiseaseCompletedNCT00528424Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's ContractureCompletedNCT00528606Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's DiseaseCompletedNCT02267460Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)CompletedNCT02724644Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Post Approval Commitment StudyCompletedNCT01444729

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Retreatment of Recurrent Dupuytren's ContracturesCompletedNCT01498640Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc